Press coverage about Halozyme Therapeutics (NASDAQ:HALO) has trended somewhat positive recently, Accern Sentiment Analysis reports. The research firm ranks the sentiment of news coverage by monitoring more than 20 million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Halozyme Therapeutics earned a news sentiment score of 0.17 on Accern’s scale. Accern also assigned news headlines about the biopharmaceutical company an impact score of 92 out of 100, indicating that recent news coverage is extremely likely to have an effect on the company’s share price in the next few days.

These are some of the news headlines that may have impacted Accern Sentiment Analysis’s scoring:

Several brokerages have recently commented on HALO. Zacks Investment Research raised Halozyme Therapeutics from a “sell” rating to a “hold” rating in a research report on Friday, May 12th. BidaskClub raised Halozyme Therapeutics from a “hold” rating to a “buy” rating in a research report on Friday, June 16th. Barclays PLC reaffirmed an “overweight” rating and issued a $16.00 target price on shares of Halozyme Therapeutics in a research report on Friday, June 23rd. ValuEngine upgraded Halozyme Therapeutics from a “sell” rating to a “hold” rating in a report on Friday, June 2nd. Finally, Canaccord Genuity set a $16.00 price objective on Halozyme Therapeutics and gave the stock a “buy” rating in a report on Wednesday, July 26th. One analyst has rated the stock with a sell rating, five have issued a hold rating and five have assigned a buy rating to the company. The stock currently has an average rating of “Hold” and an average target price of $14.84.

Shares of Halozyme Therapeutics (NASDAQ HALO) traded up 2.31% during midday trading on Thursday, hitting $12.82. The stock had a trading volume of 761,856 shares. Halozyme Therapeutics has a 1-year low of $8.18 and a 1-year high of $15.20. The firm’s market capitalization is $1.79 billion. The company’s 50 day moving average price is $13.39 and its 200-day moving average price is $13.07.

Halozyme Therapeutics (NASDAQ:HALO) last released its quarterly earnings results on Tuesday, May 9th. The biopharmaceutical company reported ($0.26) earnings per share for the quarter, missing the consensus estimate of ($0.25) by $0.01. The company had revenue of $29.60 million for the quarter, compared to analyst estimates of $30.79 million. During the same quarter in the previous year, the business posted ($0.16) EPS. The business’s revenue was down 30.4% compared to the same quarter last year. Equities analysts predict that Halozyme Therapeutics will post ($0.98) earnings per share for the current year.

WARNING: “Halozyme Therapeutics (NASDAQ:HALO) Earns Daily Media Impact Rating of 0.17” was first posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this report on another domain, it was illegally copied and reposted in violation of U.S. & international copyright & trademark legislation. The correct version of this report can be read at https://www.thecerbatgem.com/2017/08/03/somewhat-positive-media-coverage-extremely-likely-to-affect-halozyme-therapeutics-nasdaqhalo-share-price-updated-updated-updated.html.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc is a biotechnology company focused on developing and commercializing oncology therapies. The Company operates in research, development and commercialization of human enzymes and other drug candidates. The Company’s segment also includes research and development activities and product sales of Hylenex recombinant.

Insider Buying and Selling by Quarter for Halozyme Therapeutics (NASDAQ:HALO)

Receive News & Stock Ratings for Halozyme Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halozyme Therapeutics Inc. and related stocks with our FREE daily email newsletter.